‹ All episodes

The BioInsights Podcast

Exploring the landscape of novel targets & pathways in immuno-oncology

December 04, 2023 BioInsights
The BioInsights Podcast
Exploring the landscape of novel targets & pathways in immuno-oncology
Chapters
Chapters
1:01
Could you briefly describe your past experiences in cancer research and your current role at iTeos Therapeutics?
2:32
Could you give background on the novel targets and pathways development platform at iTeos? How do these represent an advance on previous work?
5:27
Can you tell me more about the research and development pipeline that this work fuels?
7:57
There's been an increased interest surrounding personalized medicine, do you think this will help with the development of personalized medicine?
8:57
What impact is being made by small-molecule targets and do you see any specific areas that require more focus?
10:18
Is there any progress in antibody targets, and how can they be further developed?
12:20
What challenges are currently facing the I-O field in terms of targeted therapies and how could these be addressed?
14:35
Finally, what are some key goals and priorities for your role and iTeos as a whole in the future?
Info
The BioInsights Podcast
Exploring the landscape of novel targets & pathways in immuno-oncology
Dec 04, 2023
BioInsights

Lauren Coyle, Editor, Immuno-Oncology Insights, speaks to Yvonne McGrath, Chief Scientific Officer, iTeos Therapeutics, about the current and emerging novel targets and pathways for the use of cancer therapy in the I-O field with a focus on small molecules and antibody targets.

Share
Apple Podcasts Spotify Amazon Music Overcast Castro Castbox +
Show Notes Chapter Markers

Lauren Coyle, Editor, Immuno-Oncology Insights, speaks to Yvonne McGrath, Chief Scientific Officer, iTeos Therapeutics, about the current and emerging novel targets and pathways for the use of cancer therapy in the I-O field with a focus on small molecules and antibody targets.

1:01
Could you briefly describe your past experiences in cancer research and your current role at iTeos Therapeutics?
2:32
Could you give background on the novel targets and pathways development platform at iTeos? How do these represent an advance on previous work?
5:27
Can you tell me more about the research and development pipeline that this work fuels?
7:57
There's been an increased interest surrounding personalized medicine, do you think this will help with the development of personalized medicine?
8:57
What impact is being made by small-molecule targets and do you see any specific areas that require more focus?
10:18
Is there any progress in antibody targets, and how can they be further developed?
12:20
What challenges are currently facing the I-O field in terms of targeted therapies and how could these be addressed?
14:35
Finally, what are some key goals and priorities for your role and iTeos as a whole in the future?